Drug profile · INN
cedazuridine
INAQOVI
cedazuridine (INAQOVI) is a cytidine deaminase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — cedazuridine
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 0
- Programs
- 3
- Data quality
- 0.84
Quick answer
cedazuridine (INAQOVI) is a cytidine deaminase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Cytidine deaminase inhibitor
Primary target: Cytidine deaminase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is cedazuridine?
cedazuridine (INAQOVI) is a cytidine deaminase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for cedazuridine?
INAQOVI is a marketed brand name for cedazuridine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of cedazuridine?
cedazuridine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.